Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions
- 15 February 2024
- journal article
- review article
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 9 (4) , 366-382
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council
This publication has 51 references indexed in Scilit:
- Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in EuropeThe Lancet Gastroenterology & Hepatology, 2018
- Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic reviewThe Lancet Global Health, 2017
- Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic reviewInternational Journal of Drug Policy, 2017
- Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis CAmerican Journal of Gastroenterology, 2017
- Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive studyCMAJ Open, 2016
- Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist TherapyAnnals of Internal Medicine, 2016
- Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject DrugsSubstance Use & Misuse, 2016
- Public health and international drug policyThe Lancet, 2016
- Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United StatesAnnals of Internal Medicine, 2015
- Understanding Barriers to Hepatitis C Virus Care and Stigmatization From a Social PerspectiveClinical Infectious Diseases, 2013